Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561100 | 0.89 | MAOA (0.46) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL30223645 | 0.89 | MAOA (0.46) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL29498303 | 0.87 | MAOB (0.48) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL560342 | 0.87 | MAOB (0.48) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL564845 | 0.85 | MAOA (0.46) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL18227270 | 0.84 | MAOA (0.41) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL19327165 | 0.84 | GYS1 (0.42) | MAOAMAOBCREBBPADRB2GYS1 | |
| SCHEMBL20285626 | 0.82 | NR3C2 (0.38) | ADRB2ADRB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28944096 | 0.82 | ADRB2 (0.43) | MAOAMAOBCREBBPADRB2ADRB1 | |
| SCHEMBL12594506 | 0.81 | ADRB2 (0.54) | MAOAMAOBADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115678936-A | Method for selectively synthesizing chiral alcohol and epoxy compound | 广东东阳光药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| CN-110087729-A | One kind has the dual-function compound of quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2019-08-02 | — | — | CN | disclosed |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | REDDY, G. Pratap (IN) | 2018-08-28 | — | — | US | disclosed |
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | REDDY, G. Pratap (IN) | 2017-09-14 | — | — | US | disclosed |
| EP-1917253-B1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8420809-B2 | Process for the manufacturing of betamimetics | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20110124859-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124859-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20100022770-A1 | PROCESS FOR THE MANUFACTURING OF BETA MIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022770-A1 | PROCESS FOR THE MANUFACTURING OF BETA MIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2125759-A2 | METHOD FOR PRODUCING BETAMIMETICS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008090193-A2 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1917253-A1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| WO-2007020227-A1 | METHOD FOR PRODUCING BETAMIMETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | MAOA 1291/4885MAOB 1583/4885CREBBP 3887/4885 |
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | CYP4A11, CYP11B1, CYP11B2 | MAOA 391/4885MAOB 360/4885CREBBP 2529/4885 |
| US-20070088160-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | ADRA1D, ADRB1, ADRA1A | MAOA 175/4885MAOB 200/4885CREBBP 1818/4885 |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | CYP4A11, CYP11B1, CYP11B2 | MAOA 367/4885MAOB 308/4885CREBBP 2605/4885 |
| US-20100022770-A1 | PROCESS FOR THE MANUFACTURING OF BETA MIMETICS | ADRB1, ADRA1D, ADRB3 | MAOA 314/4885MAOB 240/4885CREBBP 2918/4885 |
| US-20110124859-A1 | PROCESS FOR THE MANUFACTURING OF BETAMIMETICS | ADRA1D, ADRB1, ADRA1A | MAOA 175/4885MAOB 200/4885CREBBP 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.